Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13444608 | 1.00 | GAA (0.44) | GAAMEN1KMT2AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL7430822 | 0.97 | GAA (0.48) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4495411 | 0.94 | GAA (0.44) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL18320613 | 0.91 | MEN1 (0.43) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL31037172 | 0.89 | CXCR4 (0.45) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL30191205 | 0.87 | CXCR4 (0.43) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL29408147 | 0.87 | GAA (0.54) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL123812 | 0.87 | GAA (0.54) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL29144954 | 0.87 | GAA (0.54) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL31561764 | 0.85 | GAA (0.36) | GAAMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025105341-A1 | METAL PATTERNING MATERIAL, PENTAFLUOROSULFANYL COMPOUND, METAL PATTERNING THIN FILM, ORGANIC ELECTROLUMINESCENT ELEMENT, ELECTRONIC APPARATUS, AND METAL PATTERN FORMING METHOD | 東ソー株式会社 | 2025-05-22 | — | — | WO | claimed |
| WO-2025028487-A1 | MATERIAL FOR METAL PATTERNING, HETEROCYCLIC COMPOUND, THIN FILM FOR METAL PATTERNING, ORGANIC ELECTROLUMINESCENT ELEMENT, ELECTRONIC DEVICE, AND METHOD FOR FORMING METAL PATTERN | 東ソー株式会社 | 2025-02-06 | — | — | WO | claimed |
| WO-2024248132-A1 | METAL PATTERNING MATERIAL, HETEROCYCLIC COMPOUND, THIN FILM FOR METAL PATTERNING, ORGANIC ELECTROLUMINESCENCE ELEMENT, ELECTRONIC APPARATUS, AND METAL PATTERN FORMATION METHOD | 東ソー株式会社 | 2024-12-05 | — | — | WO | claimed |
| CN-117105872-B | Benzodiazepine compound and preparation method and application thereof | 徐州医科大学 | 2024-10-15 | — | — | CN | claimed |
| CN-115141153-A | Benzodiazepine compound and preparation method and application thereof | 徐州医科大学 | 2022-10-04 | — | — | CN | claimed |
| EP-2240486-B1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINE | SANOFI SA (FR) | 2015-09-09 | — | — | EP | claimed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | claimed |
| US-8598177-B2 | Imidazopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-12-03 | — | — | US | claimed |
| WO-2013126156-A1 | NITRIC OXIDE DONATING SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST COMPOUNDS AND OPHTHALMIC COMPOSITIONS | BAUSCH & LOMB INCORPORATED (US) | 2013-08-29 | — | — | WO | claimed |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI (FR) | 2012-08-16 | — | — | US | claimed |
| EP-1583745-A1 | 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-10-12 | — | — | EP | claimed |
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | claimed |
| WO-2004063163-A1 | 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| EP-1089977-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 2001-04-11 | — | — | EP | claimed |
| WO-1999067219-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | claimed |
| US-5985869-A | USEFUL AS VASODILATORS, HYPOTENSIVE AGENTS, WATER DIURETICS, PLATELET AGGLUTINATION INHIBITORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1999-11-16 | — | — | US | claimed |
| EP-0951466-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-10-27 | — | — | EP | claimed |
| WO-1998028268-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | claimed |
| EP-0623118-B1 | CARBAMATE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO WELLCOME SPA (IT) | 1998-05-13 | — | — | EP | claimed |
| US-5559230-A | VASOPRESSIN ANTAGONISTS, QUINOLINES, BENZAZEPINES, VASODILATION, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | GAA 3614/4885MEN1 746/4885KMT2A 3872/4885 |
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | GAA 2158/4885MEN1 1551/4885KMT2A 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.